MedTrace Logo

Influenza Vaccine Post Allogeneic Transplant

NCT01215981 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2017-12-28

Study results available
· View outcomes & findings →

Summary

Study Design:

This is a randomized, single center study to evaluate immune responses to the seasonal influenza vaccine in allogeneic hematopoietic stem cell transplant (HSCT) recipients who receive one vaccine or two vaccine doses one month apart. In addition, a cohort of healthy adult volunteers will be recruited as controls to confirm immune response to a single influenza vaccine.

Conditions

  • Hematopoietic Stem Cell Transplant
  • Hematologic Malignancy

Interventions

BIOLOGICAL

Influenza vaccine

One dose of inactivated hemagglutinins of influenza A (H1N1, H3N2) and influenza B

BIOLOGICAL

Influenza vaccine

Two doses of inactivated hemagglutinins of influenza A (H1N1, H3N2) and influenza B

Sponsors & Collaborators

  • Masonic Cancer Center, University of Minnesota

    lead OTHER

Principal Investigators

  • Michael Verneris, M.D. · Masonic Cancer Center, University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01215981 on ClinicalTrials.gov